Finding new drugs to block HIV protein interactions
Identification of HIV Rev-Rev interaction inhibitors by a high throughput, small molecule, cell-free screen
['FUNDING_R21'] · YALE UNIVERSITY · NIH-10923198
This study is looking for new small molecules that can help stop the HIV virus from making copies of itself, which could lead to better treatment options for people living with HIV, especially those who haven't had success with current medications.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10923198 on ClinicalTrials.gov |
What this research studies
This research focuses on discovering new small molecules that can inhibit the interaction of the HIV Rev protein, which is crucial for the virus's ability to replicate. Using a high-throughput, cell-free screening method, the team will test various compounds to identify those that effectively disrupt this interaction. This approach aims to develop novel therapeutic options for HIV patients, particularly for those who may not respond well to existing treatments. By optimizing their assay system, the researchers hope to efficiently evaluate potential drug candidates in a laboratory setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who may benefit from new therapeutic options due to resistance or intolerance to current medications.
Not a fit: Patients who are not infected with HIV or those who are already effectively managed on current antiretroviral therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new HIV treatments that are more effective and have fewer side effects.
How similar studies have performed: While there have been some compounds in clinical trials targeting HIV Rev, this specific approach using a cell-free screening method is relatively novel and has not been extensively tested.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUTTON, RICHARD — YALE UNIVERSITY
- Study coordinator: SUTTON, RICHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus